Newcastle University, RVI, Division of Psychiatry, Institute of Neuroscience, Newcastle upon Tyne, UK.
World J Biol Psychiatry. 2010 Mar;11(2):81-109. doi: 10.3109/15622970903555881.
These guidelines are based on a first edition that was published in 2002, and have been edited and updated with the available scientific evidence until September 2009. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute bipolar depression in adults.
The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (A-F). As these guidelines are intended for clinical use, the scientific evidence was finally assigned different grades of recommendation to ensure practicability.
We identified 10 pharmacological monotherapies or combination treatments with at least limited positive evidence for efficacy in bipolar depression, several of them still experimental and backed up only by a single study. Only one medication was considered to be sufficiently studied to merit full positive evidence.
Although major advances have been made since the first edition of this guideline in 2002, there are many areas which still need more intense research to optimize treatment. The majority of treatment recommendations is still based on limited data and leaves considerable areas of uncertainty.
本指南基于 2002 年发布的第一版进行编辑和更新，以纳入截至 2009 年 9 月的现有科学证据。其目的是提供一个有关成人急性双相抑郁治疗的所有科学证据的系统综述。
这些指南的数据来源于 MEDLINE 和 EMBASE 检索、临床试验数据库 clinicaltrials.gov、重要会议的最新进展以及各种国家和国际治疗指南。其科学严谨性被归类为六个证据等级（A-F）。由于这些指南旨在用于临床，因此最终根据实用性为科学证据分配了不同级别的推荐。
我们确定了 10 种药理学单药治疗或联合治疗方法，它们对双相抑郁的疗效至少有有限的阳性证据，其中一些仍处于实验阶段，仅由一项研究支持。只有一种药物被认为研究充分，值得充分的阳性证据。
尽管自 2002 年第一版指南以来已经取得了重大进展，但仍有许多领域需要更深入的研究以优化治疗。大多数治疗建议仍基于有限的数据，存在相当大的不确定性。
Zotero 插件